Ever Supreme Bio Technology Co., Ltd

6712

TW0006712003

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
207 ^TWD	-2.13%		+3.50%	+5.88%

Mar. 29	Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 15	Ever Supreme Bio Technology Co., Ltd Announces to Distribute Dividends for the Period January 1, 2023 to December 31, 2023	CI

Ever Supreme Bio Technology Co., Ltd authorizes a Buyback Plan.

August 14, 2023

The Board of Directors of Ever Supreme Bio Technology Co., Ltd has authorized a buyback plan on August 15, 2023.

Latest news about Ever Supreme Bio Technology Co., Ltd

Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Ever Supreme Bio Technology Co., Ltd Announces to Distribute Dividends for the Period January 1, 2023 to December 31, 2023	Mar. 15	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 12	CI
Ever Supreme Bio Technology Co., Ltd announces an Equity Buyback for 2,000,000 shares, for TWD 1,070 million.	23-08-15	CI
Ever Supreme Bio Technology Co., Ltd authorizes a Buyback Plan.	23-08-14	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
Ever Supreme Bio Technology Co., Ltd Announces Cash Dividend, Payable on June 21, 2023	23-05-12	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Ever Supreme Bio Technology Co., Ltd Announces Phase IIa IND for UMSC01 in Patients with Acute Myocardial Infarction Was Granted Permission by Taiwan FDA	23-03-24	CI
Ever Supreme Bio Technology Co., Ltd Announces Submission of A Phase a IND for UMSC01 in Patients with Acute Myocardial Infarction to Taiwan FDA	23-01-09	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-24	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-09	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-11	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-11	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-23	CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-12	CI
Ever Supreme Bio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-26	CI
Ever Supreme Bio Technology Co., Ltd.(GTSM:6712) added to S&P Global BMI Index	19-09-23	CI
Ever Supreme Bio Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-12	CI
Ever Supreme Bio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-28	CI

Chart Ever Supreme Bio Technology Co., Ltd

Duration

Period

Chart Ever Supreme Bio Technology Co., Ltd

More charts

Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
EVER SUPREME BIO TECHNOLOGY CO., LTD	+5.88%	465M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals